Breadcrumb Home News Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer Source: Halda | Date: 08/14/2025 Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer Image Click here to view the full article Startups & Spinouts Alumni Faculty Industry New Haven
